A Phase 3, International, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study of Denufosol Tetrasodium Inhalation Solution in Patients with Cystic Fibrosis Lung Disease and FEV, => 75% but =<110% Predicted

Grants and Contracts Details

StatusFinished
Effective start/end date8/1/084/30/11

Funding

  • Inspire Pharmaceuticals: $196,418.00